+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 1Year - 45Years
All Genders
Healthy Volunteers
ID07509047

Phase II Age-Descending Study to Assess Safety and Immune Response of Cholera Conjugate Vaccine With or Without Aluminum Phosphate in Adults and Children in Cholera-Endemic Areas

Led by International Vaccine Institute · Updated on 2026-04-03

390

Participants Needed

1

Research Sites

39 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and immune response of the OSPrTTHc cholera conjugate vaccine CCV with and without an alum adjuvant in adults and children living in cholera-prone areas. This phase II randomized controlled study aims to find the best dosing schedule and formulation for CCV in different age groups. The trial includes participants aged 1 to 45 years and compares effects of single and two-dose regimens of the vaccine, including a placebo group and an active comparator group using Euvichol4-Plus, an oral cholera vaccine. The study divides 390 participants into three age groups adults 18-45 years, older children 5-17 years, and younger children 1-4 years. Each group is randomized to receive various combinations of the CCV vaccine with or without alum, placebo injections, or Euvichol4-Plus oral doses. Vaccinations are given by intramuscular injection or orally, with doses spaced either 2 weeks or 6 months apart depending on the group. Safety data is reviewed after each cohort before younger groups begin vaccination to ensure study safety. Participants will have blood samples taken to measure antibody responses against cholera bacteria before and after vaccination, assessing immune reaction at 28 days post first and second doses. Researchers will track adverse events shortly after each dose and throughout the study, which lasts approximately six months. The study will monitor serious side effects, immune response levels, and other health indicators to guide future vaccine use in cholera-endemic regions.

CONDITIONS

Brief Title

Age-descending Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Adults and Children

Research Team

N

Naveena D'Cor, MD

T

Tarun Saluja, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here